Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Apr;18(4 Suppl 1):7-8.

Efficacy and Safety of Mirikizumab as Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Results From the Phase 3 LUCENT-1 Study

No authors listed

Efficacy and Safety of Mirikizumab as Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Results From the Phase 3 LUCENT-1 Study

No authors listed. Gastroenterol Hepatol (N Y). 2022 Apr.
No abstract available

PubMed Disclaimer

Figures

Figure 7.
Figure 7.
Clinical remission at week 12 among patients with moderately to severely active ulcerative colitis who received mirikizumab or placebo as induction therapy in the phase 3 LUCENT-1 study. IV, intravenous. Adapted from D’Haens G et al. ECCO abstract OP26. J Crohns Colitis. 2022;16(suppl 1).
See this image and copyright information in PMC

References

    1. Sandborn WJ, Ferrante M, Bhandari BR et al. Efficacy and safety of mirikizumab in a randomized phase 2 study of patients with ulcerative colitis. Gastroenterology. 2020;158(3):537–549.e10. - PubMed
    1. D’Haens G, Kobayashi T, Morris N et al. Efficacy and safety of mirikizumab as induction therapy in patients with moderately to severely active ulcerative colitis: results from the phase 3 LUCENT-1 study [ECCO abstract OP26]. J Crohns Colitis. 2022;16(suppl 1) - PubMed

LinkOut - more resources